ArticleJournal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract2026
Increasing Neoadjuvant Radiation for Rectosigmoid Cancer: An Unintended Consequence of Modern Rectal Cancer Care?
Article in Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundRectal cancer outcomes have improved with advances, including neoadjuvant radiation (NART), yet its utility for rectosigmoid cancer (RSJC) remains uncertain. We hypothesized that multimodality rectal cancer care has led to increased use of NART in rectosigmoid cancer (RSJC). Our objectives were to 1) assess the use of NART over time in RSJC and 2) identify factors associated with its use.
methodsThe National Cancer Database was reviewed (2004-2022) for adults with clinical Stage II-III rectosigmoid cancer who underwent surgery. The use of NART in these patients was examined over time, comparing stages. Multivariable logistic regression was used to identify patient and hospital factors associated with receiving NART.
resultsOf 49,506 patients, 8,591 (17.4%) received NART. Use increased over time in Stages IIIa (8.5% to 17.3%, OR 1.05, 95% CI 1.02-1.07) and IIIb/c (17.7% to 33.3%, OR 1.07, 95% CI 1.06-1.08). On multivariable analysis, factors associated with NART included male sex (aOR 1.24, 95% CI 1.17-1.32), lower Charlson-Deyo score (aOR 1.37, 95% CI 1.11-1.69, 0 vs 3), and higher stage (aOR 2.0, 95% CI 1.76-2.27 for IIIa; aOR 3.83, 95% CI 3.57-4.10 for IIIb vs II). Patients at high-volume hospitals (>26 cases/year) had lower odds (OR 0.71, 95% CI 0.61-0.82 vs <8/year).
conclusionNART in RSJC increased over time for Stage III disease, with multiple factors influencing its use. Due to the lack of specific treatment guidelines for RSJC, a multidisciplinary review, standardized anatomic definitions, and development of data-backed guidelines are recommended.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.